Analyst consensus rating
Gilead Sciences Analyst Rating: Buy
GILD is rated Buy by 27 analysts with a $157.41 target. As of 2026-08-25.
Direct answer
Gilead Sciences's consensus rating is Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $157.41.
Forecast evidence checked August 25, 2026.
Get free Gilead Sciences email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $147.73
- Average price target
- $157.41
- High price target
- $180.00
- Low price target
- $123.00
- Low target gap
- -16.7%
- Target upside
- +6.6%
- High target gap
- +21.8%
- Target range width
- 38.6%
- Consensus rating
- Buy
- Analysts
- 27
- Evidence date
- August 25, 2026
- Valid through
- September 1, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Gilead Sciences?
Gilead Sciences has a verified Buy consensus. The same dataset has an average price target of $157.41.
How far are Gilead Sciences's low and high targets from the recorded price?
The low target implies -16.7%, while the high target implies +21.8%.
How many analysts are included in Gilead Sciences's consensus?
The verified consensus includes 27 analysts.
How is Gilead Sciences's target upside or downside calculated?
The average target of $157.41 is divided by the recorded price of $147.73, then one is subtracted to produce +6.6%. This does not guarantee a future return.
When was Gilead Sciences's analyst forecast verified?
The data was verified on 2026-08-25. The dataset is valid through 2026-09-01.